Lamisil and Prostatitis - a phase IV clinical study of FDA data

Summary:

Prostatitis is found among people who take Lamisil, especially for people who are 50-59 old, have been taking the drug for 6 - 12 months.

The phase IV clinical study analyzes which people take Lamisil and have Prostatitis. It is created by eHealthMe based on reports of 13,046 people who have side effects when taking Lamisil from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 06, 2023

13,046 people reported to have side effects when taking Lamisil.
Among them, 7 people (0.05%) have Prostatitis.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 13,650 Lamisil users for its effectiveness, alternative drugs and more.

What is Prostatitis?

Prostatitis (inflammation of the prostate gland) is found to be associated with 1,053 drugs and 529 conditions by eHealthMe.

Number of Lamisil and Prostatitis reports submitted per year:

Time on Lamisil when people have Prostatitis *:

Age of people who have Prostatitis when taking Lamisil *:

Common drugs people take besides Lamisil *:

Common side effects people have besides Prostatitis *:

Nephritis Interstitial (a kidney condition characterized by swelling in between the kidney tubules): 3 people, 42.86%
Thrombocytopenia (decrease of platelets in blood): 3 people, 42.86%
Blood Creatinine Abnormal: 2 people, 28.57%
Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 28.57%
Wound: 1 person, 14.29%
Disease Progression: 1 person, 14.29%
Drug Effect Prolonged: 1 person, 14.29%
Drug Hypersensitivity: 1 person, 14.29%
Drug Ineffective: 1 person, 14.29%
Electrocardiogram Abnormal: 1 person, 14.29%

Common conditions people have *:

Nail Tinea (fungal infection of nail): 3 people, 42.86%

* Approximation only. Some reports may have incomplete information.

Do you take Lamisil and have Prostatitis?

Check whether Prostatitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Prostatitis and when was it recovered:

Prostatitis in Lamisil

Expand to all the drugs that have ingredients of terbinafine hydrochloride:

Prostatitis and drugs with ingredients of terbinafine hydrochloride (7 reports)

Alternative drugs to, pros and cons of Lamisil:

Lamisil (13,650 reports)

Common Lamisil side effects:

Rashes (redness): 949 reports
Itching: 743 reports
Fever: 646 reports
Fatigue (feeling of tiredness): 599 reports
Weight decreased: 568 reports

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Prostatitis treatments and more:

Prostatitis (7,120 reports)

COVID vaccines that are related to Prostatitis:

Common drugs associated with Prostatitis:

All the drugs that are associated with Prostatitis:

Prostatitis (1,053 drugs)

Common conditions associated with Prostatitis:

All the conditions that are associated with Prostatitis:

Prostatitis (529 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride (the active ingredients of Lamisil) and Lamisil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.